Genmab — Maj 2021
-
Lyt denne uge med om en positiv
opbremsning i Genmabs aktiekurs, hvorvidt kryptovalutaer er faldet til ro og om Norwegian taber flyvehøjde? Få også et bud på, om der er mere i vente efter det store comeback for danske aktier og en status på de seneste små danske selskabers børsentre. Det og meget mere i afsnit 67 af #Investeringspodcasten med Hansen og Larsen. https://www.youtube.com/watch?v=I8ibjBVtRwk&t=20s -
Det var en ny mand som skulle lave overskriften.Jeg får den lavet om.
-
Nohope...Lyder jeg som en sur negativ shorter i podcasten.
-
Oversigt med links til ProInvestors 22 nye FB-grupper https://www.proinvestor.com/index.php?p=debat_1&postid=93825
-
Pæn omsætning i luk....
-
God morgen.
-
Asien: Stigninger på baggrund af optimisme og teknisk omlægning https://www.proinvestor.com/investornyt/675481/asien-stigninger-pa-baggrund-af-optimisme-og-teknisk-omlaegning-ny
-
Fredagens aviser med SAS, Matas og Novo Nordiskhttps://www.proinvestor.com/investornyt/675476/fredagens-aviser-med-sas-matas-og-novo-nordisk
-
indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer.html
-
did we know this: KCR Cap
@KcrCap$HALO has patent protection on ENHANZE through 2024 in Europe and 2027 in the US. Royalty rates drop by 50% upon patent expiration, but royalties can still be collected for 10 years following commercial launch https://twitter.com/KcrCap/status/1398041938645995520
-
Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.17565
-
this is in Korean, from the Prof who will present on amivantamab at ASCO http://www.dreamdrug.com/Users/News/NewsView.html?ID=276681
-
Langtidsoverlevelse forbedret i MM https://haematologisktidsskrift.dk/sygdomme/myeloma/846-langtidsoverlevelse-vokser-voldsomt-for-myelomatosepatienter.html
-
Bispecific antibodies in review: from cell line development to manufacturing
With the advent of a technology that targets two different epitopes simultaneously, growth in the global bispecific antibody market has accelerated in recent years. Dr Kevin Robinson spoke to Gregory Bleck, Vice President of Research and Development at Catalent Biologics, to discover more about the pros, cons and applications of these innovative therapies
(www.manufacturingchemist.com)
-
@Sukkeralf was there anything interesting in that Lava presentation?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind